The Stages of Eczema: From Ecosystem Collapse to Barrier Recovery

Eczema (atopic dermatitis) is not a static condition—it is a dynamic, highly active skin state characterized by periodic flares of inflammation, intense itching, and structural barrier breakdown. Red, itchy, and inflamed skin.

Standard clinical frameworks often treat flares as mysterious immune overreactions to be muted with topical steroids or coated in heavy petroleum. But looking at the data through an ecological and biophysical lens reveals that the severity and duration of an atopic dermatitis flare are governed by three tightly linked pillars:

• Immune system sensitivity (Th2/Th22 cytokine cascades and inflammatory signaling)
• Trigger intensity (Environmental exposures and microbial ecosystem shifts, including Staphylococcus aureus dysbiosis)
• Skin barrier strength (Acid mantle pH, Natural Moisturizing Factor [NMF] depletion, and ceramide scaffolding)

In this guide, we break down the distinct stages of an atopic dermatitis flare, the biophysical mechanics driving each phase, and how to move beyond the "suppress and coat" mindset toward true, long-term barrier resilience.

For decades, standard clinical guidelines have approached eczema flares through a simple two-part strategy: suppress the immune response using topical corticosteroids or immunosuppressive medications, and sterilize or heavily coat the skin with antimicrobial washes or heavy petroleum occlusives.

While acute symptom suppression can offer temporary relief during a severe flare, treating the skin like a sterile, inanimate surface creates a dangerous paradox. Indiscriminate antimicrobials (such as daily hypochlorous acid (HOCl) sprays or bleach baths) and high-potency topical steroids do not selectively target pathogenic bacteria like Staphylococcus aureus. Instead, they frequently collateral-damage beneficial commensal microbes—such as Staphylococcus epidermidis—which actively produce antimicrobial peptides (AMPs), ferment glycerol into protective short-chain fatty acids, and maintain the skin's natural acid mantle (Kong et al., 2012; Nakatsuji et al., 2017).

When the cutaneous microbiome is wiped clean while leaving the biophysical barrier broken—characterized by elevated pH, depleted Natural Moisturizing Factors (NMF), and disorganized ceramide profiles—it leaves behind an open ecological niche. Pathogenic S. aureus rapidly recolonizes the compromised barrier, triggering a cycle of recurring flares and chronic inflammation.

To break this cycle, we must evaluate how an eczema flare evolves at the cellular and microbial level across each stage.

Atopic eczema, or atopic dermatitis, is a dynamic condition that can evolve through different stages. These stages are defined by the primary mechanisms at play and can be used to tailor treatments to address specific symptoms.

We will discuss the characteristics of acute, subacute, and chronic eczema, including what you can expect and what actions you should consider taking at each stage.

When a flare lasts for months, it settles into the chronic stage. The skin changes visually and structurally: it becomes leathery and thickened (lichenified), scaly, discolored, and trapped in relentless itching and dryness.

Conventional clinical guidelines often blame this stage on "constant scratching" and prescribe ever-increasing doses of high-potency topical steroids or systemic immunosuppressants. 

But blaming itchy skin for scratching misses the underlying biological cause: the skin is stuck in a cellular and microbial feedback loop that standard treatments fail to break.

In chronic eczema, the tissue switches from a simple inflammatory reaction to a persistent, self-sustaining loop driven by two main factors:

1. Pathogenic Biofilms: Staphylococcus aureus stops acting like isolated bacteria and starts producing a sticky matrix called a biofilm. This protective shield locks the bacteria onto the skin, shelters them from your immune system, and continuously leaks toxins into the lower layers of the skin (Kathuria et al., 2019).
2. Turned-Off Barrier Genes: Chronic inflammatory signals (specifically cytokines IL-4, IL-13, and IL-22) tell your skin cells to stop producing critical structural proteins: filaggrin (FLG), loricrin (LOR), and involucrin (IVL) (Guttman-Yassky et al., 2011). Without filaggrin, your skin cannot produce Natural Moisturizing Factors (NMF) on its own—meaning no matter how much standard lotion you put on top, the skin remains chemically incapable of holding onto water.

Furthermore, while acute flares are dominated by Th2 immune signals, chronic flares shift to involve Th1 and Th22 signaling pathways (Bei, 2012), resulting in structural skin thickening as the body attempts to shield itself from ongoing tissue damage.

Simply slathering stronger steroids on top of a bacterial biofilm doesn't fix the underlying machinery. To resolve chronic eczema, management strategies must focus on breaking the biological feedback loop through targeted, data-backed interventions:

• Disrupt Biofilms, Protect Commensals: Use targeted prebiotic and ecosystem-friendly approaches to break up S. aureus biofilms without indiscriminately wiping out beneficial commensals like S. epidermidis.
• Re-Enable Natural Moisturizing Factor (NMF) Synthesis: Restore acid mantle pH so endogenous enzymes can convert remaining filaggrin fragments into amino acids, rebuilding the skin's internal hydration engine.
• Rebuild the Lipid Scaffold: Deliver physiological ceramides and practice consistent, barrier-identical moisturizing to reinforce the stratum corneum while inflammatory cytokine signals cool down.
• Systematic Environmental & Gut Investigation: Look beyond topical treatments by evaluating stress, environmental exposures, and supporting the gut-skin axis through targeted review of diet and nutrition.
• Rethink Pharmaceutical Escalation: Conventional care relies on stepping up to higher-potency topical steroids or long-term topical calcineurin (TC) inhibitors. While these can temporarily reduce inflammatory noise, they must be paired with active barrier reconstruction.
• Evaluate Targeted Phototherapy & Systemics: For severe, non-responsive chronic cases, targeted phototherapy (specifically NB UV-B) or systemic immunosuppressive medications (including monoclonal antibodies, JAK inhibitors, or oral steroids) can serve as a temporary circuit breaker while you rebuild the physical barrier beneath.

Recovering from an eczema flare is not just a passive process of "soothing the skin"—it is an active biological sequence of ecological succession and biophysical rebuilding. 

Just as a forest gradually regenerates after a fire, your skin must rebuild its microbial ecosystem, acid mantle, and cellular scaffolding step by step.

Because structural proteins and lipid lamellae take time to synthesize, healing is rarely a perfectly straight line. Temporary setbacks can happen if an environmental trigger or pH shift disrupts the fragile new tissue. Understanding the biological milestones below makes it much easier to track real progress:

What Is Happening Biologically as Your Skin Heals:

1. Inflammation & Surface Heat Subsides: As Th2 inflammatory cytokine signaling drops, localized skin temperature normalizes and swelling calms down.
2. Acid Mantle Re-Acidification: The stratum corneum restores its natural acidic microenvironment (). This shuts down hyperactive kallikrein (KLK) serine proteases, preventing your skin from digesting its own structural rivets (Elias et al., 2008).
3. Tight Junction Resealing: In the epidermal layer, skin cells upregulate essential proteins like Claudin-1 and Occludin, locking down the cellular gaps that previously allowed water to escape and environmental allergens to penetrate (De Benedetto et al., 2011).
4. Commensal Microbes Return: Friendly commensals like Staphylococcus epidermidis recolonize the tissue, releasing natural short-chain fatty acids and antimicrobial peptides (AMPs) that keep pathogenic S. aureus from rebounding (Myles et al., 2018; Nakatsuji et al., 2017).
5. Temporary Surface Peeling & Flaking: As damaged, outer corneocytes shed to reveal newly formed tissue, you may notice brief superficial peeling. This is a normal sign of active cellular turnover—not a failure of moisture.
6. Ceramide Lamellae Re-Assembly: Your skin cells resume producing long-chain ceramides and Natural Moisturizing Factors (NMF). This turns off the persistent itch signal, softens thickened (lichenified) skin, and allows discoloration to gradually fade.

As your skin completes this biophysical repair, its structural resilience increases. A fully restored barrier and balanced microbiome can tolerate exposures that previously triggered an instant flare-up—whether that means environmental changes or foods that previously agitated a compromised gut-skin axis (see our guide on diet and nutrition).

Managing atopic dermatitis is not about reacting to flares after they erupt—it is about maintaining a resilient biophysical barrier and a balanced cutaneous microbiome every single day.

Once acute inflammation subsides, long-term flare prevention relies on three actionable pillars:

1. Protect the Acid Mantle: Avoid harsh alkaline soaps, heavy synthetic surfactants, or unnecessary daily antimicrobial sprays (like HOCl) that strip beneficial S. epidermidis and elevate stratum corneum pH.
2. Replenish Structural Lipids Daily: Don't just coat dry skin in petroleum; actively deliver physiological ceramides and practice barrier-identical moisturizing to maintain lipid lamellar organization.
3. Track Ecological Perturbations: Monitor how your skin reacts to seasonal changes, stress, and environmental triggers. Identifying subtle shifts early allows you to adjust your barrier support before an ecosystem collapse occurs.

Real, lasting skin health is built by working with your skin's biology—not by continuously nuking its microbiome or suppressing its natural repair pathways.

Have you experienced the shift from standard symptom suppression to true barrier and microbiome support? What strategies have made the biggest impact in your skin journey?

Share your thoughts and experiences in the comments below—your real-world insights help strengthen our entire community.

References

1. Bei, C. (2012). Early immunological cascades and cytokine shifts in acute vs. chronic atopic dermatitis. Current Allergy and Asthma Reports.
2. De Benedetto, A., et al. (2011). Tight junction defects in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 127(3), 773-786.
3. Elias, P. M., et al. (2008). Stratum corneum acidification in cutaneous biology and pathology. Journal of Allergy and Clinical Immunology, 121(6), 1337-1343.
4. Guttman-Yassky, E., et al. (2011). Major immune molecular pathways in atopic dermatitis and their therapeutic implications. Journal of Allergy and Clinical Immunology, 127(6), 1420-1432.
5. Hachem, J. P., et al. (2003). Sustained neutral pH accelerates filaggrin degradation and barrier disruption. Journal of Investigative Dermatology, 121(2), 345-353.
6. Iwase, T., et al. (2010). Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and colonization. Nature, 465(7296), 346-349.
7. Kathuria, S., et al. (2019). Staphylococcus aureus biofilm formation in atopic dermatitis and its role in disease persistence. Journal of Investigative Dermatology, 139(6), 1210-1218.
8. Kong, H. H., et al. (2012). Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Research, 22(5), 850-859.
9. Myles, I. A., et al. (2018). First-in-human trial of topical Roseomonas mucosa for atopic dermatitis. JCI Insight, 3(9), e120608.
10. Nakamura, Y., et al. (2013). Staphylococcus aureus delta-toxin induces mast cell degranulation and promotes atopic dermatitis. Nature, 503(7476), 397-401.
11. Nakatsuji, T., et al. (2017). Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus in atopic dermatitis. Science Translational Medicine, 9(378), eaah4680.
12. Van Smeden, J., et al. (2014). The importance of free fatty acid chain length for skin barrier maturation and ceramide organization. Journal of Lipid Research, 55(3), 523-530.